

Certificate of Participation (2024)

BioVendor-Laboratorni Medicina A.S.

Karasek 1767/1, Brno, 62100, Czech Republic

This certificate confirms participation and performance for BioVendor-Laboratorni Medicina A.S. on 09 June 2025 for the following EMQN CIC EQAs.

EQA	Performance status
LUNG CANCER (NSCLC) [Plasma]	Pass

This certificate should be read in conjunction with the Individual Laboratory Report (ILR) which contains the detailed feedback and performance data.

Signed on behalf of EMQN by:

Dr. Simon Patton (CEO)

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.





EMQN Office Unit 4, Enterprise House, Pencroft Way, Manchester Science Park, Manchester, United Kingdom, M15 6SE +44 161 757 1591 Tel: Email: office@emqn.org

INDIVIDUAL LABORATORY REPORT (ILR) - Lab 3560

SCHEME:

LUNG CANCER (NSCLC) [Plasma]

SEASON: 2024

Case 1				
Assessment Category		Comments (& deductions ²)		
Genotyping	2.00	Correct result reported (0)		
Interpretation		Not marked		
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)		

Case 2		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	Correct result reported (0)
Interpretation		Not marked
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)

Case 3			
Assessment Category	Score ¹	Comments (& deductions ²)	
Genotyping	2.00	Correct result reported (0)	
Interpretation		Not marked	
Patient Identifiers & Clerical Accuracy	2.00	All essential patient identifiers present and no significant clerical errors (0)	
General Comments	Your laboratory does not provide clinical interpretation and therefore your reports have not been assessed for the interpretation category. Thank you for participating in the 2024 Lung cancer (NSCLC) (Plasma) EQA scheme; we look forward to you joining us again in 2025.		

Published: 05 June 2025

Page 1 of 2

¹ Maximum score is 2.00

² Deductions from the maximum score

^a Green >= Scheme mean, Orange < Scheme mean, Red Poor performance. NRS no results submitted. WDS withdrew from scheme

[©] Copyright EMQN. No part of this document may be copied, distributed or published in any form without the written permission of the EMQN

SUMMARY OF YOUR PERFORMANCE IN THIS SCHEME

Assessment Category

Genotyping

Interpretation

Patient Identifiers & Clerical Accuracy

Scheme result (SATISFACTORY or POOR)



Report approved and authorised by Simon Patton (05 June 2025) on behalf of EMQN. Signed:



Published: 05 June 2025

© Copyright EMQN. No part of this document may be copied, distributed or published in any form without the written permission of the EMQN

Page 2 of 2

¹ Maximum score is 2.00

² Deductions from the maximum score

S Green >= Scheme mean, Ornage < Scheme mean, Red Poor performance.
NRS no results submitted. WDS withdrew from scheme